US-based medical device company TransEnterix has completed the acquisition of the surgical robotics division of Italian healthcare firm Sofar for $99.8m.

Sofar has developed the Telelap ALF-X advanced robotic system for minimally invasive surgery, which has an active CE Mark.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Under the deal, TransEnterix acquired all intellectual property and other assets, employees and contracts related to the Telelap ALF-X robotic system.

"The combination of SurgiBot and ALF-X will allow TransEnterix to address a larger market opportunity with compelling patient, surgeon and hospital value."

TransEnterix paid $25m in cash to Sofar and offered $43.7m worth of shares of its common stock, based on the closing price of $2.81 as of 18 September.

The deal will also include the payment of $31.1m to Sofar in three additional tranches based on the achievement of negotiated milestones.

TransEnterix president Todd Pope said: "The combination of SurgiBot and ALF-X will allow TransEnterix to address a larger market opportunity with compelling patient, surgeon and hospital value.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

"We believe this combination accelerates our commercialisation timeline and revenue ramp as we can immediately begin selling the ALF-X in many markets globally."

Telelap ALF-X, a next-generation robotic surgical system, was developed to carry out minimally invasive laparoscopic surgery.

The Telelap ALF-X system was developed by Sofar in collaboration with the European Commission’s Joint Research Centre (JRC), which is a multi-port robotic system that provides surgeons with new technology such as eye tracking and haptics.

TransEnterix is also involved in the development and commercialisation of the SurgiBot system, a robotically enhanced laparoscopic surgical platform that enables the surgeon to be patient-side within the sterile field.

The company noted the SurgiBot system has not yet received approval for sale in any market.

In June, the company submitted a 510(k) application with US Food and Drug Administration (FDA) for clearance of the SurgiBot system.

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now